Chelation Partners Announces Issuance of U.S. Patent Covering Composition of Matter for DIBI and Related Compounds for Controlling Infections

Chelation Partners, a Canadian company focused on medical indications related to iron availability including infectious disease, cancer and inflammatory disorders, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Pat. No. 10,709,784 on July 14, 2020 relating to DIBI, its lead infection control product.